1. Home
  2. KROS
  3. KROS News

Latest Keros Therapeutics Inc. (KROS) News on November 4, 2025

Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
KROS

Zacks

14 days ago

Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?

KROS

MT Newswires

15 days ago

Keros Therapeutics Launches Tender Offer for Up to $194.4 Million of Shares

KROS

MT Newswires

20 days ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday on Interest Rate Cut Expectations

KROS

MT Newswires

20 days ago

Keros Therapeutics to Buy Back Shares From Adar1 Capital, Pontifax for $181 Million

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
KROS

GlobeNewswire

20 days ago

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year
KROS

Simply Wall St.

25 days ago

Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
KROS

GlobeNewswire

2 months ago

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
KROS

TipRanks

5 months ago

McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
KROS

Benzinga

5 months ago

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

KROS

MT Newswires

5 months ago

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says

KROS

MT Newswires

5 months ago

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32

KROS

MT Newswires

5 months ago

Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
KROS

PR Newswire

5 months ago

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

KROS

MT Newswires

5 months ago

Keros to Return $375 Million to Shareholders Following Strategic Review

Keros Announces Return of $375 Million in Excess Capital to Stockholders
KROS

GlobeNewswire

5 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
KROS

GlobeNewswire

5 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC
KROS

BioPharma Dive

5 months ago

Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial
KROS

Insider Monkey

5 months ago

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial

KROS

MT Newswires

5 months ago

Update: Keros Therapeutics Shares Drop; Cibotercept Development Halted, Jobs Cut

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
KROS

Benzinga

5 months ago

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

KROS

MT Newswires

5 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday

KROS

MT Newswires

5 months ago

Keros Therapeutics to Discontinue Cibotercept's Development in Pulmonary Arterial Hypertension; Plans to Cut Workforce by 45%

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
KROS

GlobeNewswire

5 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees
KROS

GlobeNewswire

5 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
KROS

PR Newswire

5 months ago

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
KROS

GlobeNewswire

6 months ago

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point
KROS

Simply Wall St.

6 months ago

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
KROS

PR Newswire

6 months ago

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
KROS

GlobeNewswire

6 months ago

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Reinforces Commitment to Maximizing Stockholder Value
KROS

GlobeNewswire

6 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

KROS

MT Newswires

6 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

KROS

MT Newswires

6 months ago

Keros Therapeutics Stockholder ADAR1 Seeks Business Restructuring Alleging Prolonged Underperformance

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
KROS

PR Newswire

6 months ago

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations
KROS

Simply Wall St.

6 months ago

Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
KROS

Zacks

6 months ago

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
KROS

GlobeNewswire

6 months ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Implied Volatility Surging for Keros Therapeutics Stock Options
KROS

Zacks

6 months ago

Implied Volatility Surging for Keros Therapeutics Stock Options

Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz
KROS

TipRanks

7 months ago

Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz

KROS

MT Newswires

7 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

KROS

MT Newswires

7 months ago

Update: Keros Therapeutics Shares Rise After Board Initiates Review of Strategic Alternatives

Keros Therapeutics considers sale amid investor pressure
KROS

Pharmaceutical Technology

7 months ago

Keros Therapeutics considers sale amid investor pressure

KROS

MT Newswires

7 months ago

Sector Update: Health Care Stocks Lean Lower Premarket Thursday

KROS

MT Newswires

7 months ago

Sector Update: Health Care

KROS

MT Newswires

7 months ago

Keros Therapeutics Board Initiates Review of Strategic Alternatives

Keros Therapeutics Announces Review of Strategic Alternatives
KROS

GlobeNewswire

7 months ago

Keros Therapeutics Announces Review of Strategic Alternatives

KROS

MT Newswires

7 months ago

Truist Cuts Price Target on Keros Therapeutics to $25 From $43, Keeps Buy Rating

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
KROS

GlobeNewswire

7 months ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
KROS

Zacks

7 months ago

Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
KROS

Zacks

8 months ago

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
KROS

GlobeNewswire

8 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
KROS

Zacks

8 months ago

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
KROS

GlobeNewswire

8 months ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
KROS

GlobeNewswire

9 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
KROS

Simply Wall St.

9 months ago

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
KROS

Zacks

9 months ago

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
KROS

Zacks

9 months ago

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?

KROS

MT Newswires

9 months ago

Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal

KROS

MT Newswires

9 months ago

Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
KROS

GlobeNewswire

9 months ago

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
KROS

Zacks

9 months ago

Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround

KROS

MT Newswires

10 months ago

Wedbush Downgrades Keros Therapeutics to Neutral From Outperform

Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks
KROS

Zacks

10 months ago

Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks

KROS

MT Newswires

10 months ago

Oppenheimer Cuts Price Target on Keros Therapeutics to $23 From $63, Maintains Outperform Rating

KROS

MT Newswires

10 months ago

Sector Update: Health Care Stocks Rise Premarket Wednesday

KROS

MT Newswires

10 months ago

Top Premarket Decliners

KROS

MT Newswires

10 months ago

Sector Update: Health Care

KROS

MT Newswires

10 months ago

Keros Therapeutics Voluntarily Halts Phase 2 Trial for Cibotercept Over Pericardial Effusion Concerns; Shares Drop Pre-Bell

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
KROS

GlobeNewswire

10 months ago

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

KROS

MT Newswires

10 months ago

Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating

KROS

MT Newswires

a year ago

Guggenheim Downgrades Keros Therapeutics to Neutral From Buy

Keros Therapeutics price target raised to $28 from $11 at Wells Fargo
KROS

TipRanks

a year ago

Keros Therapeutics price target raised to $28 from $11 at Wells Fargo

Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug
KROS

Investor's Business Daily

a year ago

Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug

KROS

MT Newswires

a year ago

Top Midday Decliners

KROS

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

KROS

MT Newswires

a year ago

Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush Says

KROS

MT Newswires

a year ago

BTIG Downgrades Keros Therapeutics to Neutral From Buy; Shares Plunge

KROS

MT Newswires

a year ago

TD Cowen Downgrades Keros Therapeutics to Hold From Buy

KROS

MT Newswires

a year ago

William Blair Downgrades Keros Therapeutics to Market Perform From Outperform

KROS

MT Newswires

a year ago

Wedbush Adjusts Price Target on Keros Therapeutics to $47 From $84, Keeps Outperform Rating

Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
KROS

Investor's Business Daily

a year ago

Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study

KROS

MT Newswires

a year ago

Sector Update: Health Care

KROS

MT Newswires

a year ago

Top Premarket Decliners

KROS

MT Newswires

a year ago

Keros Therapeutics Shares Drop After Voluntary Halt of Two Treatment Arms in TROPOS Trial

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
KROS

GlobeNewswire

a year ago

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
KROS

GlobeNewswire

a year ago

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Takeda licensed for anaemia therapy by Keros Therapeutics
KROS

Pharmaceutical Technology

a year ago

Takeda licensed for anaemia therapy by Keros Therapeutics

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
KROS

Benzinga

a year ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

KROS

MT Newswires

a year ago

Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
KROS

GlobeNewswire

a year ago

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
KROS

GlobeNewswire

a year ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)
KROS

Simply Wall St.

a year ago

Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
KROS

GlobeNewswire

a year ago

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
KROS

GlobeNewswire

a year ago

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
KROS

GlobeNewswire

a year ago

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

KROS

MT Newswires

a year ago

Cantor Fitzgerald Initiates Keros Therapeutics at Overweight

KROS

MT Newswires

a year ago

Scotiabank Initiates Keros Therapeutics at Sector Outperform

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
KROS

GlobeNewswire

a year ago

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

KROS

MT Newswires

a year ago

Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
KROS

GlobeNewswire

a year ago

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
KROS

Investor's Business Daily

a year ago

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Share on Social Networks: